Projects per year
Fingerprint
Dive into the research topics where Paul F. Riska is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Grants
- 2 Finished
-
MYCOBACTERIOPHANGE INTERACTION WITH M TUBERCULOSIS
National Institute of Allergy and Infectious Diseases
7/15/98 → 6/30/04
Project: Research project
-
-
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
ACTT-4 Study Group, Sep 2022, In: The Lancet Respiratory Medicine. 10, 9, p. 888-899 12 p.Research output: Contribution to journal › Article › peer-review
26 Scopus citations -
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
ACTT-3 study group members, Dec 2021, In: The Lancet Respiratory Medicine. 9, 12, p. 1365-1376 12 p.Research output: Contribution to journal › Article › peer-review
52 Scopus citations -
Unexpected case of cryptococcal meningoencephalitis in a patient with long-standing well-controlled HIV infection
Yoon, H. A., Riska, P. F., Jain, R., Morales, C. & Pirofski, L. A., Jun 2021, In: Medical Mycology Case Reports. 32, p. 14-16 3 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Remdesivir for the treatment of COVID-19 — Final report
ACTT-1 Study Group Members, Essential Regulatory Documents Group Team (ERDG Team), DMID CROMS Study Information Office Team (SIO Team), Safety Oversight Committee Support Team (SOCS Team) & DMID CROMS Teleconferencing Team, Nov 5 2020, In: New England Journal of Medicine. 383, 19, p. 1813-1826 14 p.Research output: Contribution to journal › Article › peer-review
Open Access4025 Scopus citations -
The emperor's new clothes: Prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant staphylococcus aureus bloodstream infections (PROVIDE)
Antibacterial Resistance Leadership Group, Apr 15 2020, In: Clinical Infectious Diseases. 70, 8, p. 1536-1545 10 p.Research output: Contribution to journal › Article › peer-review
75 Scopus citations